Sign In
Buy ADMA
$8.46
-0.210 (-2.42%)
At Close: Jul 31, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options If you purchased or a
New York, New York--(Newsfile Corp. - August 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August
/PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9,
New York, New York--(Newsfile Corp. - August 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick and Foti, LL
/PRNewswire/ -- Kahn Swick and Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
06:46pm, Friday, 31'st Jul 2026
Adma Biologics (ADMA) closed the most recent trading day at $8.46, moving 2.42% from the previous trading session.
NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and M
ADMA AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit- HBSS
02:41pm, Friday, 31'st Jul 2026
SAN FRANCISCO, July 31, 2026 /PRNewswire/ -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) that a securities fraud class action lawsuit has been filed. The lawsuit focuses on
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 31, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies i
ADMA Biologics (NASDAQ: ADMA) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
01:20pm, Friday, 31'st Jul 2026
NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. , a top complex litigation law firm, is investigating ADMA Biologics (NASDAQ: ADMA) (“ADMA Biologics” or the “Company”) for po
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Friday, 31'st Jul 2026
New York, New York--(Newsfile Corp. - July 31, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options If you purchased or a
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 10, 2026 in ADMA Biologics, Inc. Lawsuit - ADMA
10:23am, Friday, 31'st Jul 2026
NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA).
SAN DIEGO, July 31, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities b
